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Abstract
Rationale The cannabinoid system has risen to the fore-
front in the development of novel treatments for a number
of pathophysiological processes. However, significant side
effects have been observed in clinical trials raising concerns
regarding the potential clinical utility of cannabinoid-based
agents. Understanding the neural circuits and neurochemical
substrates impacted by cannabinoids will provide a better
means of gaging their actions within the central nervous
system that may contribute to the expression of unwanted
side effects.
Objectives In the present study, we investigated whether
norepinephrine (NE) in the limbic forebrain is a critical deter-
minant of cannabinoid receptor agonist-induced aversion and
anxiety in rats.
Methods An immunotoxin lesion approach was combined
with behavioral analysis using a place conditioning paradigm
and the elevated zero maze.
Results Our results show that the non-selective CB1/CB2
receptor agonist, WIN 55,212-2, produced a significant
place aversion in rats. Further, NE in the nucleus
accumbens was critical for WIN 55,212-2-induced aversion
but did not affect anxiety-like behaviors. Depletion of NE
from the bed nucleus of the stria terminalis was ineffective
in altering WIN 55,212-2-induced aversion and anxiety.
Conclusions These results indicate that limbic, specifically
accumbal, NE is required for cannabinoid-induced aversion
but is not essential to cannabinoid-induced anxiety.
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Introduction
The endocannabinoid system has been implicated in a
variety of physiological functions due to abundant expres-
sion of its receptors and endogenous ligands in the central
nervous system (CNS; Herkenham et al. 1991; Mackie
2005; Mackie 2008) as well as in adipose tissue, gastro-
intestinal tract, skeletal muscle, heart, and the reproductive
system (for review, Pacher et al. 2006). The endocannabinoid
system controls emotional reactivity, motivated behaviors,
and energy homeostasis. In the brain, the cannabinoid
receptor type 1 (CB1r) is the most abundant while the
cannabinoid receptor type 2 (CB2r) is found mainly in cells
of the immune and hematopoietic systems (Piomelli
2003). The diverse localization of the endocannabinoid
system underscores its importance as a potential target in
the treatment of a variety of disorders. However, when
targeting the endocannabinoid system, a high number of
unwanted side effects occur, as evidenced by increased
incidence of anxiety and depression in obese patients
treated with the CB1r antagonist, rimonabant (Steinberg
and Cannon 2007). Cannabinoid agonists have also been
shown to induce anxiety and dysphoria (Reilly et al.
1998; Williamson and Evans 2000). Hence, identifying
neurochemical targets of cannabinoids is essential. Some
studies have suggested that the dysphoric/aversive effects
seen upon cannabinoid administration are due to its anxio-
genic properties (McGregor et al. 1996; Ghozland et al.
2002). However, conclusive evidence is lacking to support
this hypothesis.
The present study explored the role of limbic norepineph-
rine (NE) in cannabinoid-induced aversion and anxiety. NE
is involved in cognition and attention (Aston-Jones et al.
1991) as well as in the pathophysiology of mood disorders
(Heninger et al. 1996; Anand and Charney 2000). Previous
studies have shown an interaction between the cannabinoid
system and the NE system in areas such as the prefrontal
cortex (PFC) (Oropeza et al. 2005, 2007; Page et al. 2007),
nucleus accumbens (Acb; Carvalho et al. 2010), locus
coeruleus (Oropeza et al. 2005; Scavone et al. 2010) and
the nucleus of the solitary tract (NTS) (Jelsing et al. 2009;
Carvalho et al. 2010). Limbic regions such as the Acb and
bed nucleus of the stria terminalis (BNST) have been
implicated in aversive and anxiety-like behaviors (Davis
1998; Aston-Jones et al. 1999; Ventura et al. 2007;
Carlezon and Thomas 2009). In the present study, we
investigated the role of NE in the Acb and BNST in
cannabinoid-induced aversion and anxiety. For this pur-
pose, an immunotoxin lesion approach was used to target
NE fibers in the Acb and BNST and behavioral tests were
performed on rats after administration of a CB1r/CB2r
agonist, WIN 55,212-2.
Methods
Subjects
Sixty four male Sprague-Dawley rats (Harlan Laboratories,
Indianapolis, IN, USA) weighing 220–250 g were housed
two or three per cage in a controlled environment (12-h
light schedule, temperature at 20°C). Food and water were
provided ad libitum. The care and use of animals were
approved by the Institutional Animal Care and Use
Committee of Thomas Jefferson University and were
conducted in accordance with the NIH Guide for the care
and use of laboratory animals. All efforts were made to
minimize animal suffering and reduce the number of
animals used.
Surgery
Rats were anesthetized with an intraperitoneal (i.p.)
injection of a saline solution containing a cocktail of
Ketamine HCl (100 mg/kg; Phoenix Pharmaceutical, Inc.
St. Joseph, MO, USA) and Xyla-Ject (2 mg/kg; Phoenix
Pharmaceutical, Inc.) and subsequently placed in a stereo-
taxic surgical frame (Stoelting Corp., Wood Dale, IL,
USA). The anesthesia was maintained by administration
of isoflurane (Webster Veterinary Supply, Inc., Sterling,
MA, USA) through a nose cone. Animals received bilateral
injections of saporin conjugated with an antibody against
dopamine-beta-hydroxylase (DSAP, Chemicon International,
Inc., Temecula, CA, USA; 0.21 μg/μl in phosphate buffer
(PB), pH 7.4) or control solution with non-conjugated saporin
(SAP, Advanced Targeting Systems, San Diego, CA, USA,
0.0441 μg/μl in PB) into the Acb (n=32, 250 nl bilaterally;
AP, 1.7 mm rostral to bregma; ML, ±0.8 mm; DV, −7.0 mm)
or the BNST (n=32, 300 nl bilaterally; AP, 0.4 mm caudal
to bregma; ML, ±4.0 mm; DV, −7.4 mm, with an angle
of 19.6°), according to Rat Brain Atlas of Paxinos and
Watson (1997) coordinates. The dose of DSAP and SAP
used was based on previously published studies (Ritter et
al. 2001; Ritter et al. 2003). The volume of DSAP and
SAP injected at each site was determined from pilot
experiments in our laboratory using a similar protocol.
Previous immunohistochemical studies indicated that a
period of 2 weeks was sufficient for transport of the
immunotoxin and degeneration of the affected neurons
(Wrenn et al. 1996; Ritter et al. 2003). Therefore, animals
were given 15–18 days before the start of the behavioral
tests described below.
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Drug preparation and administration
WIN 55,212-2 (Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in 5% dimethyl sulfoxide (DMSO; Fisher
Scientific, Fair Lawn, NJ, USA) in 0.9% saline and
injected i.p. (3.0 mg/kg) in a volume of 1 ml/kg body
weight. Vehicle injections consisted of 5% DMSO in
0.9% saline.
Place conditioning
An unbiased place conditioning procedure was used so that
the side of the apparatus used to conditioned animals was
counterbalanced in all the groups. The paradigm consisted
of three phases: pre-test, conditioning, and test. On pre-test
day (day 1), animals were placed in the apparatus and
allowed to freely explore both sides of the apparatus for
20 min. The time spent in each side was recorded by an
investigator and animals with preference for one side higher
than 200 s were removed from the study (eight animals of a
total of 64). During the conditioning phase (days 2–6), the
rats were injected twice daily. In the morning, animals were
injected with vehicle and confined to one side of the
apparatus for 45 min. In the afternoon, animals were
injected with WIN 55,212-2 (3.0 mg/kg) and confined to
the opposite side for 45 min. Control groups of animals
received vehicle in both sessions. On the test day (day 7),
animals were placed in the apparatus and allowed to
explored both sides for 20 min. The test trial was recorded
on camera and time spent in each side was measured by an
investigator. No injection was given to the animals on the
test day.
Spatial reference memory test
Verifying that the lesion of noradrenergic input to the Acb
and BNST did not alter spatial memory performance,
animals were tested in the spatial reference memory test
(Morris 1984). Animals were tested 4 days following place
conditioning. WIN55,212-2 was not injected at any point
during the test period. This control experiment was
included to verify that spatial memory was intact in animals
with a selective depletion of norepinephrine in the Acb and
BNST. The test was conducted in a circular black tank
(1.8 m diameter) filled to a depth of 31 cm with water at
22°C and placed in a dimly lit room with extrinsic clues.
The hidden platform remained at a fixed spatial location for
the entire acquisition period. The acquisition phase con-
sisted of four daily trials (inter-trial interval of 30–45 min.)
over 4 days. Each trial started with the animals being placed
into the water, facing the wall of the maze, at one of four
starting points: N, E, S, and W. Four different starting
positions were randomly used in each training block. A trial
was considered complete when the rat escaped onto the
platform; when this escape failed to occur within 120 s, the
animal was gently guided to the platform and an escape
latency of 120 s was recorded for that trial. Rats were
allowed to spend 10 s on the escape platform before being
returned to home cage. Time needed to reach the platform
(escape latency), length of the path described (distance
swam) and swim velocity were recorded using HVS
Image 2020 Plus tracking system (Version 9/05, HVS
Image, Buckingham, UK).
The probe trial was assessed after the last trial of the
acquisition period, removing the platform from the pool.
Animals were released on the side opposite to where the
platform was for a single trial of 60 s, during which the
percent time spent in each quadrant was measured. For
analysis, the time spent in the target quadrant was
compared with the average time spent in the remaining
three quadrants.
Elevated zero maze
The elevated zero maze (EZM) is a modification of the
elevated plus maze that is also a reliable and sensitive
model of anxiety-like behavior in rodents (Shepherd et al.
1994). The EZM consists of a black ABS plastic annular
platform (∼120 cm diameter) elevated ∼70 cm above the
ground. It is divided into four equal quadrants which are
∼20 cm wide: two opened and two closed. The two opened
quadrants are opposite each other and are surrounded by a
1 cm “lip”. The two closed quadrants are enclosed by walls
(∼27 cm high) on both the inner and outer edges of the
platform. Testing was conducted the day after the spatial
reference memory test in a dimly lit room with a constant
illumination on the opened arms of the maze. Vehicle and
WIN 55,212-2 were injected i.p. 30–35 min prior to the
start of the test. At the start of the 10 min testing session,
each rat was placed on the same opened arm facing the
center of the maze. The maze was cleaned with 65%
ethanol and dried after each testing session. Time spent in
the closed arm and total number of entries was used as the
output measure for this maze.
Locomotor activity
After the EZM, locomotor activity was assessed in a subset
of animals from each treatment group to determine whether
treatment influenced locomotor activity. Animals were
placed in a home cage-like environment within the Home
Cage Video Tracking System (Med Associates, St. Albans,
VT, USA) which includes a sound-attenuating cubicle,
video tracking interface, and Activity Monitor 5 software
(Med Associates). Distance traveled was recorded by the
video tracking system for 10 min.
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Immunohistochemistry
At the conclusion of testing, animals were deeply anesthetized
with an i.p. injection of sodium pentobarbital (60 mg/kg)
and transcardially perfused with 50 ml of heparinized saline
followed by 400 ml of 4% formaldehyde (Electron
Microscopy Sciences, Fort Washington, PA, USA) in
0.1 MPB (pH 7.4). After perfusion, brains were removed
and postfixed in the same fixative. Following post-fixation,
brains were cryoprotected in a gradient of sucrose solutions
(containing 0.1% sodium azide) of 10% and 20% sucrose
in 0.1 MPB for 1 h each and 30% sucrose for 48–72 h.
Brains were immersed in O.C.T. Embedding Compound
(Electron Microscopy Sciences, Hatfield, PA, USA) and
frozen in dry ice. Coronal sections of the forebrain (35 μm)
were cut using a Microm HM550 cryostat (Richard-Allan
Scientific, Kalamazoo, MI, USA) in multiple sets and
collected in 0.1 MPB. Every sixth section was processed
for immunohistochemical visualization of DBH immuno-
reactivity to verify the DSAP-induced lesion. Free-floating
sections were treated with 1% sodium borohydride in
0.1 MPB for 30 min. They were then rinsed with 0.1 MPB
and later washed in 0.1 M Tris saline buffer (TS, pH 7.6).
The sections were blocked in 0.5% bovine serum albumin
(BSA) in 0.1 M TS for 30 min and then washed for 5 min,
twice. Sections were incubated overnight at room temper-
ature with a mouse antibody for mouse monoclonal
antibody recognizing DBH (1:1,000, Chemicon, Millipore)
in 0.1% BSA/0.25% Triton-X 100 in 0.1 M TS. The
sections were then washed in 0.1 M TS, three times for
10 min. Then, sections were incubated in a secondary
biotin-conjugated donkey anti-mouse IgG (1:400, Jackson
ImmunoResearch, West Grove, PA, USA) in 0.1% BSA/
0.25% Triton-X 100 in 0.1 M TS for 30 min at room
temperature. Then, sections were washed in 0.1 M TS,
three times for 10 min. Sections were incubated in an
avidin-biotin complex solution (1:200, VECTASTAIN Elite
ABC Kit, Vector Laboratories, Burlingame, CA, USA) in
0.1 M TS for 30 min and then washed. Finally, a
peroxidase reaction product was achieved by incubating
sections in 22 mg of 3-3′ diaminobenzidine (Sigma-
Aldrich) containing 0.05% hydrogen peroxide.
Data analysis
Quantification of noradrenergic fibers depletion
Noradrenergic fibers were identified using an antibody
specific for DBH. Sections of SAP and DSAP animals were
labeled for DBH as described above. Sections containing
the Acb and BNST were visualized using a Leica DMRBE
microscope (Wetzlar, Germany), and darkfield images
were acquired (at ×10) using SPOT Advanced software
(Diagnostics Instruments, Inc., Sterling Heights, MI,
USA). Light intensity was kept constant for all image
acquisitions. To quantify the amount of fiber depletion,
two methods were used. For sections containing the Acb,
two to three sections per animal (comprising different
levels of the Acb as exemplified in Fig. 1c) were used for
analysis. Using Image-Pro Plus (Version 5.1, Media
Cybernatics, Bethesda, MD, USA) the area of the Acb
and the number of fibers per section and per side was
quantified. Data was analyzed as the ratio of total number
of fibers/total area analyzed and presented as percentage of
control (SAP-injected animals). Since the BNST contains
an extremely dense amount of noradrenergic fibers, it is not
feasible to count individual DBH-immunoreactive fibers.
Therefore, for sections containing the BNST, intensity of
labeling was measured using Kodak Molecular Imaging
Software (Version 4.5, Carestream Health Inc., Rochester,
NY, USA). Two to three sections containing the anterior
BNST (ranging from approximately 0.26 posterior to
bregma to a few sections posterior to 0.40 mm, Fig. 1d)
per animal was analyzed. Dorsal and ventral regions were
analyzed separately. A region of interest (ROI) was set as a
template and used to quantify all images so that the area
analyzed remained constant. Thus, data is presented as
percentage of control (SAP-injected animals) mean inten-
sity. For every section analyzed, a background value was
quantified in an area of the section lacking DBH-ir. The
background value was subtracted to the intensity of the
ROI.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 Graduate
Student Version. Behavioral data were analyzed by a two-
way ANOVA (toxin × drug). Repeated measures multi-
variate analysis of variance (ANOVARM) with day or period
of time as the within-subject factor was also used when
appropriate. One-wayANOVA, t test and post hoc Bonferroni
test were used to analyze differences between groups when
appropriate. Significance was set at p<0.05.
Results
Toxin depletion of noradrenergic fibers
Animals recovered rapidly from intracranial injections
without evidence of illness or abnormal behavior. DSAP
and SAP animals gained weight at the same rate (Fig. 1a
and b).
Immunohistochemistry for DBH in the forebrain of
DSAP and SAP-injected animals was performed to verify
the localization and the extent of the lesion. Two animals,
Psychopharmacology
Fig. 1 Effect of saporin conju-
gated with an antibody against
DBH (DSAP) injection into the
nucleus accumbens (Acb) and
into the bed nucleus of stria
terminalis (BNST). a and b
Toxin and drug treatment had no
significant effect on animals’
weight throughout the experi-
ment. c and d Schematics
adapted from the rat brain atlas
of Paxinos and Watson (1997)
showing the approximated
levels of the Acb (c) and BNST
(d) used for NE depletion
quantification (note: for the
BNST, a more caudal section
between −0.40 and −0.80 mm
was analyzed). Inset in c repre-
sent the level of the photo-
micrographs in e and g. Inset in
d represent the level of the
photomicrographs in f and h.
e-h Darkfield photomicrographs
showing DBH immunoreactivity
in the Acb (e and g) and in
the BNST (f and h) after injec-
tion of saporin or DSAP. Injec-
tion of DSAP significantly
reduced the amount of DBH
immunoreactivity by about 75%
in both the Acb (i) and BNST
(j; ***p<0.0002). ac anterior
commissure, LV lateral ventricle,
L lateral, V ventral. Scale bar
100 μm
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out of 56 without any baseline preference, were excluded
from behavioral testing due to inaccurate placement of the
toxin. Injection of SAP did not affect DBH immunoreac-
tivity (ir) when compared to vehicle-injected animals,
whereas DSAP-injected animals revealed a marked reduc-
tion of DBH-ir (Fig. 1e–h) in both the Acb and BNST.
Surrounding areas, such as the septal nuclei for the Acb and
the ventral pallidum and medial preoptic area for the BNST
were intact. Depletion of DBH fibers was quantified as
explained in the methods section and for both areas a
significant depletion of about 75% of DBH-ir fibers was
achieved using injection of DSAP when compared to SAP-
injected animals (Fig. 1i and j).
Depletion of noradrenergic fibers in the Acb reverses
the aversive effects of WIN 55,212-2
The place conditioning paradigm was used to assess the
aversive effects of WIN 55,212-2. Animals were assigned
to four groups: animals that received SAP injections and
were injected with vehicle in both sessions (SAP/vehicle,
seven animals); animals that received SAP injections and
were conditioned with WIN 55,212-2 (SAP/WIN, six
animals); animals injected with DSAP and received vehicle
in both sessions (DSAP/veh, six animals) and animals that
received DSAP injections and were conditioned with WIN
55,212-2 (DSAP/WIN, ten animals). Repeated measures
analysis revealed that the there was an overall effect of time
of testing (F(1,25)=5.849, p=0.023), meaning that the
conditioning phase affected the performance of the animals
on the test day. The analysis also showed an interaction
between the treatments (toxin and drug) (F(1,25)=4.350,
p=0.047). Further analysis showed that SAP-treated
animals that received WIN 55,212-2 spent less time in
the drug-paired chamber than the respective vehicle
group (t(11)=5.468, p<0.001), indicating that WIN
55,212-2 induced aversive-like behaviors (Fig. 2a). On
the contrary, animals depleted of NE in the Acb did not
show aversion to WIN 55,212-2 when compared with
DSAP/vehicle-treated animals (t(14)=−0.471, p=0.645)
(Fig. 2a). This suggests that noradrenergic input to the
Acb is important for the development of aversion to WIN
55,212-2.
Depletion of noradrenergic fibers in the BNST
is not implicated in the aversive effects of WIN 55,212-2
Animals injected with DSAP or SAP in the BNST were
assigned to four different groups as mentioned above for
Acb injections and conditioned in the same manner (six to
eight animals a group). Repeated measures analysis
revealed an effect of time of testing (F(1,21)=6.169, p=
0.022), meaning that the conditioning phase affected the
performance of the animals on the test day. The analysis
also revealed an interaction between time of testing and
drug (F(1,21)=4.324, p=0.050; Fig. 2b) but not between
time of testing and toxin (F(1,21)=3.403, p=0.079)
suggesting that WIN 55,212-2 is aversive in both SAP
and DSAP-treated animals and that depletion of NE in the
BNST does not reverse the effects of WIN 55,212-2.
Spatial reference memory is intact
A spatial memory test was performed to ensure that
depletion of NE from the target areas did not impair the
animals’ ability for recall that could impact findings from
the place conditioning test. To evaluate acquisition in the
water maze, a two-way ANOVA for repeated measures was
performed to assess any overall effects of factors toxin and
drug, or their interactions on latency to the platform,
distance traveled, and swim velocity during task acquisi-
tion. The analysis revealed an overall effect of trial on
latency to reach the platform (F(3,36)=62.719, p<0.0001)
and distance traveled (F(3,36)=55.930, p<0.0001), indi-
cating that all animals efficiently learned where the
Fig. 2 Effect of DSAP on the development of WIN 55,212-2-induced
place aversion. a Animals that received saporin injection in the Acb
developed place aversion to WIN 55,212-2 (3.0 mg/kg, *p<0.001
compared to SAP/Veh). This effect was blocked by injection of DSAP
into the Acb (p>0.05, compared to DSAP/Veh). b Animals that
received toxin injection into the BNST developed place aversion to
WIN 55,212-2 that was not blocked by DSAP injection (*p=0.05
compared to vehicle-treated animals)
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platform was (Fig. 3a and b). No overall effect of trial on
swim velocity was observed (F(3,36)=1.571, p=0.213;
Fig. 3b), suggesting that speed was constant throughout the
acquisition phase. Moreover, there were no statistically
significant interactions between toxin and drug for the three
parameters analyzed, indicating no difference between
groups on memory acquisition, distance traveled, and swim
velocity. Similar results were observed when the toxin was
injected in the BNST (Fig. 3a–c, right column). There was
an overall effect of trial on latency to reach the platform
(F(3,36)=55.930, p<0.0001), distance traveled (F(3,36)=
13.348, p<0.0001), and swim velocity (F(3,36)=7.274, p<
0.001). Conversely, there were no significant interactions
between toxin and drug for the three parameters analyzed
showing that all groups had similar performances in the test.
To assess memory retention, a probe trial was performed
after the last trial of the acquisition phase. Repeated measures
with time spent in the target quadrant and the average time
spent in the other three quadrants was performed with two
independent factors: toxin and drug. The analysis showed an
overall effect of time spent in the quadrants (Acb, F(1,12)=
410.008, p<0.0001; BNST, F(1,12)=53.960, p<0.0001).
There was no interaction between drug and toxin meaning
that the two factors combined did not affect the animals’
performance. T test analysis revealed that all groups spent
significantly more time in the target quadrant comparing to
the non-target quadrants (Acb, p<0.001; BNST, SAP/Veh
and DSAP/WIN p<0.001 and SAP/WIN and DSAP/Veh
p<0.005; Fig. 4a). Two-way ANOVA of distance traveled
and swim velocity during the probe trial revealed no
significant interaction between drug and toxin (Acb,
distance traveled F(1,12)=1.471, p=0.249, swim velocity
F(1,12)=1.6, p=0.23; BNST, distance traveled F(1,12)=
0.119, p=0.736, swim velocity F(1,12)=0.141, p=0.714;
Fig. 4b and c), suggesting no effect of drug or toxin on the
animals’ locomotor activity.
Fig. 3 Spatial memory acquisi-
tion is intact in animals injected
with the toxin in the Acb (left
column) and in the BNST
(right column). Depletion of
noradrenergic fibers in both the
Acb and BNST did not impair
memory acquisition. All groups
of animals performed well in the
acquisition phase of the Morris
water maze test, showing low
latency times to find the
hidden platform by day 4
(a, ***p<0.0001, ANOVARM).
All groups of animals showed
similar locomotor activity, with
no significant difference on
distance (b) and speed of swim
(c) (p>0.05, ANOVARM)
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Depletion of noradrenergic fibers to the Acb or BNST
has no effect on WIN 55,212-2-induced anxiety
Cannabinoid agonists are known to induce anxiety-like
behaviors at high doses (Viveros et al. 2005; Rutkowska et
al. 2006). To assess whether the reversal of aversive-like
behaviors was due to changes in the level of anxiety, a
group of animals was subjected to the EZM. A two-way
ANOVA crossing toxin (SAP and DSAP) and drug (vehicle
and WIN 55,212-2) treatment was performed to analyze
changes in the percentage of time spent in the closed
arms of the maze. This revealed an overall effect of drug
in both the Acb (Fig. 5a) and BNST (Fig. 5b) experiments
(F(1,12)=36.686, p<0.0001; F(1,12)=34.372, p<0.0001,
respectively), indicating that WIN 55,212-2 was anxio-
genic. There was no overall effect of toxin (F(1,12)=
3.047, p=0.106 (for the Acb); F(1,12)=3.449, p=0.088
(for the BNST)) in the time spent in the closed arm. The
analysis revealed no interaction between drug and toxin
treatment (Acb, F(1,12)=0.22, p=0.647; BNST, F(1,12)=
0.199, p=0.663), revealing that depletion of NE from the
Acb and BNST did not affect the anxiety-like behavior
induced by WIN 55,212-1.
In addition, similar results were observed when analyzing
the total number of entries into the arms of the maze (Table 1).
There was an overall effect of drug in both the Acb and
BNST experiments (F(1,12)=72.104, p<0.001), (F(1,12)=
11.108, p<0.01, respectively). There was no effect of
toxin (Acb, F(1,12)=1.182, p=0.298; BNST, F(1,12)=
0.184, p=0.184) and no interaction between drug and
toxin (Acb, F(1,12)=1.748, p=0.211; BNST, F(1,12)=
0.094, p=0.765). These results indicate an anxiogenic
Fig. 4 Spatial memory reten-
tion is intact in animals injected
the toxin in the Acb (left
column) and in the BNST
(right column). Depletion of
noradrenergic fibers in both the
Acb and BNST did not impair
memory retention. During the
probe trial (platform removed),
all groups of animals spent
significantly more time in the
target quadrant (a) compared
to the average time spent
on the other three quadrants
(*p<0.005, **p<0.001 com-
pared to target quadrant). No
significant effect was observed
in the locomotor activity shown
by no changes in the distance
(b) and speed of swim (c) during
the probe trial
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effect of WIN 55,212-2 that was not affected by depletion
of NE.
Locomotor activity
After completion of the EZM, the animal’s locomotor
activity was assessed. A two-way ANOVA crossing toxin
(SAP and DSAP) and drug (vehicle and WIN 55,212-2)
treatment revealed no effect of toxin (F(1,12)=0.539, p=
0.477) or drug (F(1,12)=0.727, p=0.411) treatment in the
animals injected in the Acb (Fig. 5c). However, in the
animals injected in the BNST it was observed an overall
effect of toxin (F(1,12)=12.387, p=0.004) but not drug
(F(1,12)=0.219, p=0.648) in the distance traveled, sug-
gesting that depletion of NE from the BNST increases
locomotor activity (Fig. 5d).
Discussion
This study examined the neurochemical and regional
substrates involved in cannabinoid-induced aversion and
anxiety. The results indicate that administration of a CB1r/
CB2r agonist induces conditioned place aversion and
anxiety. It is reported that noradrenergic transmission
within the Acb is a critical determinant for the expression
of aversion-like behavior (as measured by the place
conditioning paradigm) following exposure to a cannabi-
noid agonist. Moreover, norepinephrine depletion from the
Acb and BNST did not affect anxiety-like behaviors,
underscoring the involvement of differential circuitry in
the expression of aversion and anxiety to a cannabinoid
receptor agonist.
Fig. 5 Anxiety-like behavior
(a and b) and locomotor activity
(c and d) of animals injected
with the toxin in the Acb (a and
c) and in the BNST (b and d).
Animals injected WIN 55,212-2
(3.0 mg/kg) showed higher
anxiety levels as measured by
more time spent in the close
arms of the elevated zero maze
(a and b; *p<0.0001). Injection
of DSAP had no effect of the
anxiety levels. Toxin and drug
administration in the Acb group
had no effect on locomotor
activity (c). DSAP injection into
the BNST increased locomotor
activity independently of drug
administration (d, *p<0.005)
Table 1 Total number of entries in the elevated zero maze
Vehicle WIN 55,212-2 Total
Acb
SAP 38 (±4.183) 7.5 (±2.63) 45.5
DSAP 48.25 (±5.921) 6.5 (±3.594) 46.75
Total 78.25** 14
BNST
SAP 49 (±8.399) 25 (±11.195) 74
DSAP 40.25 (±6.575) 11.4 (±4.874) 51.64
Total 89.25* 36.4
Data represent mean of total number of entries (into opened and
closed arms), ± SEM
*p<0.01, vehicle-treated animals compared to WIN 55,212-2-treated
animals
**p<0.001, vehicle-treated animals compared to WIN 55,212-2-
treated animals
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WIN 55,212-2-induced aversion: role of limbic circuitry
The present results are in agreement with previous findings
that report cannabinoid receptor agonists to be aversive to
rats, as shown by the induction of conditioned place
aversion (McGregor et al. 1996; Sanudo-Pena et al. 1997;
Mallet and Beninger 1998; Pandolfo et al. 2009). Aversive
behaviors require emotional learning and association of
emotions with a context, therefore limbic areas such as the
PFC, BNST, and Acb have been involved in eliciting these
behaviors (Gracy et al. 2001; Levita et al. 2002; Delgado et
al. 2008). Gracy and colleagues (2001) have shown that
place aversion to naltrexone-induced opiate withdrawal is
related to neuronal activation of the shell subregion of the
Acb and the central nucleus of the amygdala (CeA).
Moreover, monoaminergic transmission in areas such as
the amygdala, PFC, BNST, and Acb has been implicated in
the development of aversive behaviors (Aston-Jones et al.
1999; Delfs et al. 2000; Ventura et al. 2007; Kerfoot et al.
2008). For instance, Aston-Jones and colleagues (1999)
have shown that blockade of beta adrenergic receptors in
the CeA attenuates the morphine withdrawal-induced place
aversion. Herein, we explored the hypothesis that NE in the
Acb and BNST is a critical determinant for the establish-
ment of cannabinoid-induced aversion. Using an immuno-
toxin lesion approach of two limbic areas (Acb and BNST),
we were able to establish the role of selected circuits
involved in the expression of aversion to cannabinoids. Both
areas are important nuclei of the limbic system, integrating
information arising from the amygdala (concerning affective
components of the behavior), from the hippocampus and
PFC (conveying contextual features from the environment),
and from the ventral tegmental area (regarding reward related
components of learning experiences; Forray and Gysling
2004; Kerfoot et al. 2008). Moreover, both the Acb and
BNST receive direct input from the NTS (Delfs et al. 1998;
Forray et al. 2000; Forray and Gysling 2004) that conveys
information regarding peripheral signals (e.g., arousal) with
limbic structures. We show that this noradrenergic input
from the NTS to the Acb is critical for the expression of
place aversion to WIN 55,212-2. To our knowledge, it is not
known whether the noradrenergic neurons projecting to the
Acb have collateral projections to other areas. This is a
potential caveat as, when lesioning NE neurons projecting to
the Acb, collateral projections to other areas could be
affected. However, we consider this a remote possibility
because depletion of NE from the BNST, which receives
much more NE than the Acb and does have collaterals to the
CeA (Roder and Ciriello 1994) and paraventricular nucleus
of the hypothalamus (Terenzi and Ingram 1995), did not
affect any of the behaviors analyzed. A more important
consideration regarding interpretation of findings from this
study relates to the fact that these animals lack NE
throughout the conditioning phase and, therefore, it is not
possible to discern whether NE is critical for the establishment
and/or, on the other hand, for the recalling of the motivational
association. However, previous studies show that impairment
of NE transmission after the learning phase does not impact
the expression of the behavior (Miranda et al. 2007; Kerfoot
et al. 2008) suggesting that NE is not required for recalling
learned associations. Nevertheless, pharmacological
approaches would be needed to better clarify the time point
in which NE is important for cannabinoid-induced aversion.
The ability of WIN 55,212-2 to induce aversion is most
likely mediated by activation of CB1r as it has been shown that
prior administration of the CB1r antagonist AM 251 prevents
WIN 55,212-2-induced aversion (Pandolfo et al. 2009). CB1r
has been localized to GABAergic neurons (Matyas et al. 2006)
in the Acb but seldom on noradrenergic neurons (Carvalho et
al. 2010). Moreover, cannabinoids have been shown to affect
both glutamate and GABA transmission in the Acb (Manzoni
and Bockaert 2001; Robbe et al. 2001). Interestingly, CB1r is
found in noradrenergic neurons of the NTS (Carvalho et al.
2010) and WIN 55,212-2 has been shown to activate NTS
neurons (Himmi et al. 1998; Jelsing et al. 2009).
We interpret the results of the present study in the
following way: WIN 55,212-2 may act on CB1 receptors
that are localized to noradrenergic neurons of the NTS,
increasing their firing rate and subsequently increasing
release of NE in the Acb. Consistent with this interpretation,
WIN 55,212-2 has been shown to lead to changes in
adrenergic receptor expression in the Acb (Carvalho et al.
2010). Moreover, one could speculate that activation of
CB1r in glutamatergic and GABAergic terminals in the Acb
may decrease the release of these amino acids, making Acb
medium spiny neurons more sensitive to NE. In addition,
other systems may be involved. For example, kappa opioid
receptors (KOR) have been shown to be critical for THC-
induced aversion (Zimmer et al. 2001; Ghozland et al.
2002). Mice lacking KOR do not show aversion to THC in
the place conditioning paradigm. Dynorphin, the endoge-
nous KOR agonist, is distributed throughout the Acb, in
axon terminals that form mostly symmetric synapses
(Khachaturian et al. 1982; Van Bockstaele et al. 1994).
Interestingly, dynorphin is also found within NTS neurons
and fibers (Fodor et al. 1994) and acute administration of
the KOR synthetic agonist U-50,488H has been shown to
increase c-fos activation of catecholaminergic NTS neurons
(Laorden et al. 2003). This can be a potential mechanism by
which dynorphin and KOR facilitate aversion to cannabi-
noids. Taken together, there are a number of potential inter-
pretations and future studies are required to carefully parse out
the nature of cannabinoid actions on the NTS/Acb circuit.
Others have shown that blockade of NE transmission
within the BNST impairs place aversion to opiate withdrawal
(Aston-Jones et al. 1999; Delfs et al. 2000). Although, in the
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present study, depletion of NE in the BNST did not affect
WIN 55,212-2-induced aversion, the possibility exists that
upon withdrawal from cannabinoid exposure, NE transmis-
sion in the BNST becomes engaged in a fashion similar to
opiate withdrawal. Future studies are required to test this
possibility.
Anxiogenic effects of WIN 55,212-2
Cannabinoid agonists have been shown to exert anxiogenic
effects in both animals and humans (Onaivi et al. 1990;
Childers and Breivogel 1998; Arevalo et al. 2001; Marco et
al. 2004; Witkin et al. 2005). Taking this into consideration,
we hypothesized, along with others (McGregor et al. 1996),
that reduction of the aversive effects of WIN 55,212-2
observed in the present study could be due to a reduction in
anxiety levels. In order to examine this, animals were tested
in the EZM. Our results are in agreement with others that
showed that WIN 55,212-2 administration induces anxiety-
like behaviors as seen by an increased time spent in the
closed arms of the maze and decreased exploration
measured by a reduction in the total number of entries.
None of these EZM outputs was affected by NE depletion
in both the Acb and BNST. These results dissociate
anxiety-like behaviors from aversive behaviors. The results
show that the same lesion that reverses the aversive
behavior (depletion of NE in the Acb) had no effect on
anxiety-like behavior. Though this fact cannot rule out an
association between anxiety and aversion to WIN 55,212-2,
it clarifies the nuclei involved in these two behaviors.
Nevertheless, it is surprising that disrupting noradrenergic
transmission in the Acb, but especially in the BNST, does not
affect anxiety-like behavior. The BNST is known to be a key
nucleus in the expression of anxiety (Davis 1998; Davis
2006) and it is a “hot spot” of noradrenergic innervation
(Forray and Gysling 2004). Hence, it is surprising that
depletion of NE did not affect the expression of anxiety.
However, little is known about the circuitry involved in
cannabinoid-induced anxiety. The fact that other stimuli
(stress, drug withdrawal) increases NE release in the BNST
and this may trigger anxiety may not hold true for
cannabinoid based agents. Moreover, the possibility exists
that a 75% reduction of noradrenergic fibers was not
sufficient to remove the noradrenergic basal tone in the
BNST. Although further studies are required, the present
results seem to suggest that CB1R-induced anxiety is not
dependent on noradrenergic transmission.
Concluding remarks
The endocannabinoid system is widely expressed in the
central and peripheral nervous system as well as immune
system. Thus, it is involved in numerous physiological
processes. Understanding how cannabinoids impact multiple
systems will help us to better manipulate the endocannabi-
noid system without engaging unwanted side effects. The
present study provides new information about the neural
circuits involved in cannabinoid-induced behaviors that may
lead to the development of potential new pharmacotherapies
for the treatment of psychiatric disorders.
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